April W. Armstrong, MD, MPH, associate dean of clinical research at Keck School of Medicine at USC, Los Angeles, California, discussed why IL-23 inhibitors should be the first consideration in the psoriasis treatment armamentarium. Erin E. Boh, MD, PhD, Joseph Chastain Endowed Chair of Clinical Dermatology, Tulane University, New Orleans, Louisiana, presented evidence supporting the first-line use of IL-17 inhibitors for patients with psoriatic disease.